Michael A Nauck

Addition of a dipeptidyl peptidase‐4 inhibitor, sitagliptin, to ongoing therapy with the glucagon‐like peptide‐1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes

J. Holst, M. Kahle, M. Nauck, 2017, Diabetes, obesity & metabolism.

Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.

Amalia Gastaldelli, A. Gastaldelli, M. Nauck, 2013, Metabolism: clinical and experimental.

Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance

Mark Ellrichmann, J. Holst, M. Nauck, 2008, Diabetes.

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.

J. Holst, M. Nauck, C. Deacon, 2004, Diabetes.

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

Murray Stewart, J. Rosenstock, M. Feinglos, 2014, The lancet. Diabetes & endocrinology.

Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.

Michael Horowitz, Liza Phillips, Antonietta Russo, 2006, The Journal of clinical endocrinology and metabolism.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

John B Buse, B. Zinman, S. Pocock, 2016, The New England journal of medicine.